We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.37%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.87B
AUM Growth
+$772M
Cap. Flow
-$1.35B
Cap. Flow %
-17.14%
Top 10 Hldgs %
73.35%
Holding
114
New
19
Increased
20
Reduced
44
Closed
6

Top Buys

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$93M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$34.7M
3
ACOR
Acorda Therapeutics
ACOR
+$33.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$29M
5
XNPT
XENOPORT, INC.
XNPT
+$18.1M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$41.4M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$35.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$25.4M
4
HALO icon
Halozyme
HALO
+$8.89M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 43.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
51
DELISTED
Zogenix, Inc.
ZGNX
$6.69M 0.09%
293,800
-50,075
-15% -$1.63M
ACGN
52
DELISTED
Aceragen Inc
ACGN
$6.58M 0.08%
11,873
-11,472
-49% -$7.85M
XNCR icon
53
Xencor
XNCR
$1.48B
$6.36M 0.08%
542,363
-7,637
-1% -$80.2K
AERI
54
DELISTED
Aerie Pharmaceuticals
AERI
$6.34M 0.08%
299,356
-644
-0.2% -$13K
NVAX icon
55
Novavax
NVAX
$1.22B
$5.54M 0.07%
61,168
-3,178
-5% -$355K
IRWD icon
56
Ironwood Pharmaceuticals
IRWD
$601M
$5.5M 0.07%
532,715
-119,400
-18% -$1.34M
TBRA
57
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$5.01M 0.06%
+44,444
New +$3.12M
LGND icon
58
Ligand Pharmaceuticals
LGND
$5.79B
$4.94M 0.06%
117,660
– –
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.5B
$4.89M 0.06%
+100,000
New +$5.15M
EPZM
60
DELISTED
Epizyme, Inc
EPZM
$4.87M 0.06%
214,012
-5,988
-3% -$182K
OSIR
61
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$4.75M 0.06%
361,530
-13,752
-4% -$215K
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
$4.74M 0.06%
+571,000
New +$5.35M
PTLA
63
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.73M 0.06%
182,591
-41,843
-19% -$1.12M
CYTR
64
DELISTED
CytRx Corp
CYTR
$4.71M 0.06%
+225,000
New +$7.98M
BLUE
65
DELISTED
bluebird bio
BLUE
$4.51M 0.06%
15,306
+6,470
+73% +$1.96M
AKTX
66
Akari Therapeutics
AKTX
$14.7M
$4.37M 0.06%
+84
New +$4.75M
TVTX icon
67
Travere Therapeutics
TVTX
$5.23B
$4.19M 0.05%
+197,178
New +$3.03M
IONS icon
68
Ionis Pharmaceuticals
IONS
$8.99B
$4.16M 0.05%
96,303
-150,733
-61% -$7.31M
BDSI
69
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.55M 0.05%
421,005
-425,000
-50% -$3.43M
FURX
70
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$3.51M 0.04%
+40,309
New +$3.11M
ENTA icon
71
Enanta Pharmaceuticals
ENTA
$365M
$3.24M 0.04%
80,957
-28,140
-26% -$1.02M
MGNX icon
72
MacroGenics
MGNX
$238M
$2.68M 0.03%
96,165
-3,835
-4% -$135K
LJPC
73
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.39M 0.03%
+221,631
New +$2.17M
MDGL icon
74
Madrigal Pharmaceuticals
MDGL
$12.5B
$2.15M 0.03%
14,286
– –
SVRA icon
75
Savara
SVRA
$1.09B
$2.04M 0.03%
+42,857
New +$2.35M
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2014 Portfolio in Review

As of Q1 2014, Baker Bros. Advisors held 114 positions worth $7.87B, up 11% from $7.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.35B in Q1 2014, closing 6 positions and reducing 44 holdings. Its most notable exit was MEDIVATION, INC., an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Acorda Therapeutics worth $37.9M.

  • Baker Bros. Advisors's largest Q1 2014 buy was Acorda Therapeutics: 8,333 shares worth $37.9M.
  • Baker Bros. Advisors added most to INTERMUNE INC in Q1 2014, an estimated $93M increase.
  • Baker Bros. Advisors's biggest Q1 2014 reduction was Arrowhead Research, cutting an estimated $41.4M.
  • Baker Bros. Advisors fully exited MEDIVATION, INC. in Q1 2014, selling an estimated $25.4M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $7.87B portfolio in Q1 2014.
  • Baker Bros. Advisors opened 19 new positions and closed 6 in Q1 2014.
  • Baker Bros. Advisors's portfolio value rose 11% quarter-over-quarter to $7.87B.

Based on Baker Bros. Advisors's 13F filing for Q1 2014, filed 15 May 2014.